The main goal of the project is to develop to the clinical stage Ia the world's first innovative biological drug WPD101 used in the treatment of glioblastoma multiforme (GBM).

GBM is the brain tumor with the highest grade of malignancy characterized by infiltrative growth or a tendency to local spread within the central nervous system. Due to the survival rate of only 14-15 months after diagnosing and the lack of effective forms of therapy, this disease is a serious problem on a global scale.

The breakthrough of the solution will be based on the use of targeted therapy against IL-13RA2 and EphA2 receptors. What's more, the planned way of administering the drug to the tumor tissue will be an advantage over standard intravenous administration, thanks to which patients will avoid the side effects associated with standard chemotherapy. The Project's result will allow patients access to innovative molecular targeted therapies as an alternative to conventional treatment.

The project includes the implementation of the following stages of R&D:

  1. Development of recombinant cytotoxins.
  2. Studies on in vitro models related to the evaluation of the specificity of the cytotoxins.
  3. In vivo studies on an animal model to assess the safety and bioavailability of the new molecule.
  4. Manufacturing a series of product in the GMP standard.
  5. Implementation of the phase Ia clinical trial to assess safety and early efficacy of the new molecule, delivered to the tumor tissue, in monotherapy of brain tumors.
  6. Implementation of the Project results will allow the Company to acquire unique know-how in the field of biotechnology, which will be the basis for building a technology platform for implementing innovative projects in Poland in the field of oncology, thus contributing to the development of the Polish biopharmaceutical sector.

This project is co-financed by the European Union from the European Regional Development Fund under the Intelligent Development Operational Program 2014-2020.
Project is implemented as part of the National Center for Research and Development: Proposal No 5/1.1.1/2017 - "Fast track", Priority I: Support for conducting R&D works by Medium and Small companies and Microenterprises, Sub-measure 1.1.1. Industrial research projects and Experimental development work projects carried out by companies. Contract No: POIR.01.01.01-00-0912/17-00.

The total value of the project: 31 435 831,75 PLN
Co-financing of the project from the EU: 21 400 477,45 PLN

R & D